- Chinese Death Star: The moon cited as the perfect launch pad for ballistic missiles
- Help wanted: Homeland Security plagued by vacancies at the top
- We are not amused: Queen’s protection officers warned to keep ‘sticky fingers’ off the royal cashews
- Unleash the crossbows: Gov. Scott Walker creates new hunting season
- Bubonic plague kills 20 in Madagascar
- G-20 diplomats fell for hacker attack promising nude photos of former French first lady Carla Bruni
- Minnesota guardsman charged with stealing private soldier data for fake IDs
- Florida appeals court rules universities can’t regulate guns
- Vladimir Putin defends Russian conservative values
- Tea Party Patriots call key GOP firing a declaration of war
Mass. gov. orders surprise pharmacy inspections
Question of the Day
BOSTON (AP) - The governor of Massachusetts is ordering surprise inspections of certain pharmacies after one was linked to a deadly nationwide meningitis outbreak.
Compounding pharmacies specialize in customizing doses for patients who have allergies or need smaller amounts.
A state health department spokesman says the first such inspection was Tuesday. He won’t reveal the name of the facility and says results of the inspection are being reviewed.
Steroid shots from a compounding center just west of Boston are suspected in the meningitis outbreak, which has sickened more than 300 people. Twenty-three people have died.
THIS IS A BREAKING NEWS UPDATE. Check back soon for further information. AP’s earlier story is below.
State officials said Tuesday they found unclean conditions including visible black specks of fungus in steroids and a leaking boiler near what was supposed to be a clean room at a pharmacy linked to a deadly outbreak of meningitis.
Gov. Deval Patrick said the state has moved to revoke the licenses of the New England Compounding Center and three pharmacists there. He also has ordered the state pharmacy board that oversees similar companies to conduct surprise inspections and take other steps to tighten oversight.
State officials said a preliminary investigation found that the NECC shipped orders from the lots of steroid shots suspected in the outbreak before its own tests came back confirming the lots were sterile. In some cases, they said, drugs went out up to 11 days before test results came back.
Officials also said the company, in Framingham, just west of Boston, operated as a drug manufacturer by producing drugs for broader use, rather than filling out specific prescriptions for specific doctors, which is all its license allowed.
The outbreak of meningitis, an inflammation of the lining of the brain and spinal cord, has sickened nearly 300 people, including 23 who died, in more than a dozen states. Each victim had received a steroid shot, mostly for back pain. Federal health officials matched the shots produced by the company to the outbreak after finding a deadly fungus in more than 50 unopened vials there but have not said how the shots were contaminated.
New state documents released this week detailed problems an outside firm hired to do an assessment found there years ago.
The state documents, obtained by The Associated Press under a public records request, say investigators in 2006 found inadequate contamination control and no written standard operating procedures for using equipment, among other problems. The problems were corrected that year, and a state inspection in May 2011 as the company prepared to update its facilities found no such issues.
In a letter sent Monday to a lawyer for NECC, the U.S. House Committee on Energy and Commerce sought nearly 10 years of documents about safety and quality issues at the company. It indicated that as far back as 2002 and 2003 officials from the Food and Drug Administration and the state conducted joint probes of the company after receiving a report about a steroid shot. Those probes preceded a 2004 joint investigation of the center by the FDA and the Massachusetts Board of Registration in Pharmacy.
In January 2006, based on several complaints, the company signed with state regulators a consent agreement in which it agreed to a full inspection of its drug compounding practices by investigators.
By Matt Kibbe
The short-term deal will assure long-term overspending
- Obama's Afghanistan experts stumped on U.S. death toll, war costs during hearing
- NAPOLITANO: A conspiracy so vast
- Comma on!: Twitter erupts over Obama-Castro 'marriage'
- All-out war breaks out in GOP over budget pact
- GOP Rep. Tim Murphy rolls out mental health legislation
- Biden guarantees victory on immigration reform
- Obama takes 'selfie' at Mandela's funeral service
- Selfie at heart of Obama fiasco to stay secret
- White House faces press revolt over access to Obama's South Africa flight
- MALCOLM/REIMER: Over-criminalization undermines respect for legal system
Independent voices from the The Washington Times Communities
Lists of top ten movies, songs, funny moments, fashion statements, automobiles, children's names, stupid celebrity moments, first dates, last dates, weddings, and much, much more.
Communities writers read and review current and past books of note. Also, news and views focusing on print and online media.
An objective, analysis-based perspective of D.C. sports as seen through the eyes of lifelong D.C. sports enthusiast, John Heibel.
Extraordinary day at Redskins Park
White House pets gone wild!
Let it snow